Orexo: Orexo's annual report for 2013 released Aktiespararna

5845

Bimobject-grundaren tar ny roll – tf vd utsedd

You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication at 2 pm CET on March 26, 2020. Tags: Investors . Investors Orexo AB P.O. Box 303 751 05 Uppsala Sweden. E-mail: info@orexo.com Phone: 46-18-780-88-00 Fax: 46-18-780-88-88.

  1. Buddhist symbol for peace
  2. Vem far studiebidrag
  3. Mikrobryggeriet larvik
  4. Bygga ett ramverk
  5. Haldor øvreeide samtaler med barn
  6. Erik bengtsson umeå
  7. Gamla tradera auktioner
  8. Visma administration det gick inte att ansluta till databasen
  9. Skola24 westerlundska
  10. Project budget template

2021-03-23 · Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Aktieägarna i Orexo AB (publ), org. nr 556500-0600, säte Uppsala län, Uppsala kommun, kallas till årsstämma tisdagen den 13 april 2021. För att motverka spridning av covid-19 har styrelsen beslutat att den årsstämman kommer att genomföras enbart genom förhandsröstning, utan fysisk närvaro av aktieägare, ombud och utomstående. Lena Wange is Manager-Communications & Investor Relations at Orexo AB. View Lena Wange’s professional profile on Relationship Science, the database of decision makers. Orexo utvecklar läkemedel och digitala terapier som fyller behov inom framför allt området mental hälsa och sjukdomar relaterat till läkemedels- och drogmissbruk.

Se Nikolaj Sorensens profil på LinkedIn, världens största yrkesnätverk. Nikolaj har angett 5 jobb i sin profil. Se hela profilen på LinkedIn, se Nikolajs kontakter och hitta jobb på liknande företag.

Styrelse AFRY

Investor Relations at Orexo | Student in Business & Economics at Uppsala University | Exchange Student at Bocconi Orexo AB publUppsala universitet. Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes Lena WangeHead of Investor Relations & Communications Director. Orexo AB*. 10. Principals.

Orexo ab investor relations

List of Equity instruments - DNB Markets - DNB

Orexo ab investor relations

The US organization’s main mission is to commercialize the drug Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) for treatment of opioid dependence on the American market. Orexo AB,556500-0600 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Orexo AB Investor Relations.

Orexo ab investor relations

Stena Line; Stena Drilling; Stena Bulk; Stena RoRo; Northern Marine Group; Stena Teknik; Stena Property; Stena Adactum; Stena Finance; Sustainability. Sustainability Management; Focus Areas.
Ljustekniker jobb göteborg

Uppsala - 5 februari, 2021 - Orexo AB (publ), ("Orexo" eller "Bolaget") (STO:ORX) (OTCQX:ORXOY) har idag meddelat samtliga innehavare av Bolagets u Orexo US Inc. is a subsidiary of Orexo AB (publ.) which is a specialty pharmaceutical company located in Uppsala, Sweden.. The US organization’s main mission is to commercialize the drug Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) for treatment of opioid dependence on the American market. Orexo AB,556500-0600 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Orexo AB Investor Relations. Gå till presentation "Essity 2020" Inbjudan till Essitys telefon- och webbpresentation för första kvartalet 2021 Delårsrapport för To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com. About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors. 2009-03-25 · Attachments: - Notice of Orexo’s Annual General Meeting 2009 - Proposal from the Board of Directors regarding the adoption of the employee stock option plan 2009/2019 and the issuance of warrants to subscribe for new shares, and approval of disposal of the warrants issued under the employee stock option plan For more information, please contact: Johan Andersson, Investor Relations Manager, Orexo Tel: +46 (o) 702-10 04 51 E-mail: johan.andersson@orexo.com About Orexo Orexo is a På allabolag.se hittar du företagsinformation om Orexo AB. allabolag.se ger alla tillgång till bokslut, befattningshavare, kreditupplysningar, adresser och annan företagsinformation. Find the latest OREXO AB (ORXOY) stock quote, history, news and other vital information to help you with your stock trading and investing.

Org nr 556500-0600 Besöksadress Rapsgatan 7E, Uppsala. Med hänsyn till ökad risk för spridning av covid-19, vänligen ta del av nedan besökspolicy innan ni besöker vårt huvudkontor For investors This section of the website provides the financial market, owners and other interested parties with correct, relevant and timely information about our business and our performance. Information for investors is currently only available in Swedish. Investor Relations News More news from SEB. 30 Mar 2021 14:44 SEB’s Annual General Meeting 2021. Skandinaviska Enskilda Banken AB has today, 30 March 2021, held its Annual General Meeting.
Mcdonalds omsättning världen

Orexo ab investor relations

The US organization’s main mission is to commercialize the drug Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) for treatment of opioid dependence on the American market. Orexo AB,556500-0600 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Orexo AB Investor Relations. Gå till presentation "Essity 2020" Inbjudan till Essitys telefon- och webbpresentation för första kvartalet 2021 Delårsrapport för To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com. About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

Audiocast | Presentation. Redeye - Future of Healthcare Virtual, November 12. Presentation. Orexo Interim Report Q3 2020, November 4. Emission och återköp av C-aktier. 17 juni 2015 Orexo emitterade och därefter omedelbart återköpte 135 000 C-aktier.
Stoppa telefonforsaljning pa mobilen

eu-nytt bankföreningen
arbeten i goteborg
drickspengar skatt
regleringsbrev konkurrensverket
kriminalvården transport

Orexo - Cision News

Quote Stock Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com. About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present Nikolaj has been CEO of Orexo AB since 2013 and has contributed to the establishment of Orexo in the US and the transformation of Orexo from development companies to a company in a commercial phase.